A Phase 4 interventional study of Diphenhydramine 50 mg and Diphenhydramine 25 mg in Nasal Congestion, sponsored by Johnson & Johnson Consumer and Personal Products Worldwide. Completed at 12 sites in United States. Open to participants aged 12 Years to 65 Years. Per ClinicalTrials.gov, last updated 2011-08-22.
Sponsored by Johnson & Johnson Consumer and Personal Products Worldwide (formerly part of Johnson & Johnson) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 65 studies in Nasal Obstruction with a site in United States — 9 open to participants now, 11 under way, 1 of them phase 3. Nasal Obstruction · United States.
Among the 65 studies in Nasal Obstruction with a site in United States, this one is the 2nd largest by enrollment of the 56 interventional ones that give a count, is one of 2 that started in 2006, is one of 4 in phase 4, and was the 4th registered.
173 studies on the registry are indexed under Nasal Obstruction; 31 are open to participants now.
Browse Nasal Obstruction studies →9 of the 65 studies in Nasal Obstruction with a site in United States are open now. Recruiting first, the newest first:
Aerin Medical · Sites in United States
Ages 22–85
Washington University School of Medicine · Sites in United States
Ages 18+
Ohio State University · Sites in United States
Ages 18–70 · Healthy volunteers
University of Michigan · Sites in United States
Ages 3–21
Endeavor Health · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 20 Nasal Obstruction studies recruiting now, 7 (35%) set no upper age limit and 11 (55%) stop at 75 or younger; 4 take children under 18; 4 take healthy volunteers.
This study: 12 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
65 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 11 · Phase 3 8 · Phase 4 4
First in 2005; this study’s year is marked. 2 started in 2006.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,021 is above the median of 70 across 139 interventional studies indexed under Nasal Obstruction.
Median enrollment 51 across the 56 interventional studies, 40 across the 9 observational. Of the 50 that completed or were terminated, 27 (54%) have results posted.
This tab as a report to print or save as PDF → With an account.
33 of 65 have an industry lead sponsor. The 10 most frequent:
This study is registered under Johnson & Johnson Consumer and Personal Products Worldwide, one of the names counted as Johnson & Johnson. Under that name alone:
Johnson & Johnson Consumer and Personal Products Worldwide is the lead sponsor of 60 studies on the registry; none are open to participants now.
Johnson & Johnson has 5 studies filed under Nasal Obstruction — fewer than ten, so there is no comparison to draw.
7 of the studies in Nasal Obstruction with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04194216Phase 3Stanford UniversityAntibiotic Prophylaxis in Rhinoplasty | 2026-12-20 |
| NCT06830109Washington University School of MedicineNasal Obstruction With Oxymetazoline and Corticosteroids | 2026-12-30 |
| NCT06163404Spirair, IncOpen-Label Study to Evaluate the Safety and Effectiveness of the Spirair Implant | 2027-03 |
| NCT07574918Aerin MedicalMeasuring Nasal Airway Changes After VivAer Treatment Using AI Analysis | 2027-05 |
| NCT05527652University of MichiganSelf-Supporting Nasopharyngeal Airway (ssNPA) Treating Upper Airway Obstruction in Hypotonia | 2027-05 |
Add all 7 to your calendar (.ics) → With an account.
Among the 65 studies in Nasal Obstruction with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The study was to determine if the drug worked to relieve nasal congestion experienced by people with seasonal allergies.
Subjects who met the inclusion/exclusion criteria were enrolled into the placebo run-in phase of the study on Day -7 (prerandomization, Visit 1). Baseline symptom scores were established during this run-in phase.
Subjects with moderate nasal congestion who took at least 80% of their study medication during the run-in phase were eligible for enrollment in the two-week double-blind phase of the study and were randomized on Day 1 (randomization, Visit 2). They were treated for two weeks with their assigned medication. The severity of signs/symptoms were evaluated by the subjects every morning and night and by the investigator at each visit on Day 7 and Day 14.
In addition, the subject and investigator provided a global evaluation of response to treatment on Day 7 and Day 14. Safety was evaluated by adverse events reported during the study, vital signs, and the incidence of somnolence.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Diphenhydramine 50 mg
Drug: Diphenhydramine 50 mg
Diphenhydramine 25 mg
Drug: Diphenhydramine 25 mg
Pseudoephedrine 120 mg
Drug: Pseudoephedrine 120 mg
Three times daily: two diphenhydramine 25 mg capsules Twice daily: one pseudoephedrine-matching placebo tablet
Also known as: Active: Lot # 070PB6 Formula # W015990-0002
Three times daily: one diphenhydramine 25 mg capsule and one diphenhydramine-matching placebo capsule Twice daily: one pseudoephedrine-matching placebo tablet
Also known as: Active: Lot # 070PB6 Formula # W015990-0002
Three times daily: two diphenhydramine-matching placebo capsules Twice daily: one pseudoephedrine 120 mg tablet
Also known as: Active: Lot # INT-06-115 Formula # W015721-0004
Change from baseline in the subject's mean reflective nasal congestion/stuffiness symptom score
Time frame: every 12-hours over the 14-day treatment period
Change from baseline in the subject's mean reflective Total Nasal Symptom (TNS) Score
Time frame: 14 Days
Change from baseline in the subject's mean instantaneous TNS Score
Time frame: 14 Days
Change from baseline in the subject's mean reflective Total SAR Symptom (TSS) Score
Time frame: 14 Days
Change from baseline in the subject's mean instantaneous TSS Score
Time frame: 14 Days
Change from baseline in the subject's mean reflective score for each of the seven remaining individual SAR symptoms, excluding nasal congestion/stuffiness
Time frame: 14 Days
Change from baseline in the subject's mean instantaneous score for each of the eight individual SAR symptoms
Time frame: 14 Days
Onset of action for diphenhydramine treatment for nasal congestion/stuffiness was determined by comparing the change from baseline in the subject's instantaneous nasal congestion/stuffiness scores for diphenhydramine versus placebo
Time frame: taken at 15, 30, 60 and 90 minutes after the initial dose. Baseline was the score taken just prior to the initial dose.
Onset of action for diphenhydramine treatment for allergic rhinitis symptoms was determined by comparing the change from baseline in the subject's instantaneous TNS scores for diphenhydramine versus placebo
Time frame: taken at 15, 30, 60 and 90 minutes after the initial dose. Baseline was the score taken just prior to the initial dose
Duration of action for diphenhydramine for treatment of nasal congestion/stuffiness was evaluated by comparing the change from baseline in the subject's mean instantaneous nasal congestion/stuffiness scores for diphenhydramine versus placebo
Time frame: taken at the six-hour trough (just prior to the 8:00 pm dose) and the 12-hour trough (just prior to the 8:00 am dose)
Duration of action for diphenhydramine for treatment of allergic rhinitis symptoms was evaluated by comparing the change from baseline in the subject's mean instantaneous TNS scores for diphenhydramine versus placebo
Time frame: taken at the six-hour trough (just prior to the 8:00 pm dose) and the 12-hour trough (just prior to the 8:00 am dose)
Time to maximal effect was assessed by a by-day analysis of the primary efficacy endpoint and select secondary endpoints
Time frame: 14 Days
Subject's global evaluation of response to treatment
Time frame: at Visits 3 and 4, analyzed separately at each visit
Change from baseline in the Investigator's TNS score
Time frame: at Visits 3 and 4, analyzed separately for each visit. Baseline was the score at Visit 1
Change from baseline in the Investigator's TSS score
Time frame: at Visits 3 and 4, analyzed separately for each visit. Baseline was the score at Visit 1
Change from baseline for each of the eight individual Investigator's SAR symptoms
Time frame: at Visits 3 and 4, analyzed separately for each visit. Baseline was the score at Visit 1
Investigator's global evaluation of the subject's response to treatment
Time frame: at Visits 3 and 4, analyzed separately for each visit
Number and percentage of subjects experiencing adverse events
Time frame: Duration of study
Change from baseline and potentially clinically important vital signs (systolic and diastolic blood pressure, pulse, and respiratory rate)
Time frame: Duration of study
Occurrence of somnolence
Time frame: Overall and weekly
The record gives a start of Nov 2006, a primary completion of May 2007 and a completion of May 2007. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Diphenhydramine
Johnson & Johnson Consumer and Personal Products Worldwide →